Last reviewed · How we verify

NCT05977829: TamAUB

Endometrial Malignancy in Breast Cancer Patients With or Without AUB

Completed Last updated 26 December 2023
What this trial tests

trial testing Ultrasound in Endometrial Neoplasms in 283 participants. Completed in 30 July 2022.

Timeline
1 January 2020
Primary endpoint
1 June 2021
30 July 2022

Quick facts

Lead sponsorUniversity of Campania Luigi Vanvitelli
StatusCompleted
Study typeOBSERVATIONAL
Enrollment283
Start date1 January 2020
Primary completion1 June 2021
Estimated completion30 July 2022
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University of Campania Luigi Vanvitelli

Who can join

Adults 43 to 70, female only, with Endometrial Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In order to assess the hysteroscopic, histopathologic, and ultrasonographic aspects of uterine monitoring in postmenopausal breast cancer patients with or without abnormal uterine bleeding (AUB), as well as to calculate the risk of endometrial cancer in women with or without AUB.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ultrasound

Trials testing the same drug.

Other recruiting trials for Endometrial Neoplasms

Currently open trials in the same condition.

Other University of Campania Luigi Vanvitelli trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05977829.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing